In recent trading, shares of Verona Pharma plc (Adderbury) (Symbol: VRNA) traded at $48.20, surpassing the average analyst 12-month target price of $47.28. When a stock reaches this target, analysts typically respond in one of two ways: either they downgrade their valuation or increase their target price. Analyst reactions might also hinge on recent developments within the company that could be driving its stock price upward.
There are seven analysts contributing to the average target for Verona Pharma plc (Adderbury), and the average is simply a numerical mean. Some analysts have more conservative targets, with one estimating a price of $36.00. Conversely, a more optimistic analyst has set a target as high as $64.00. The standard deviation among these estimates is $8.92, indicating some variability in expectations.
The significance of the average VRNA price target lies in gathering insights from various experts, reflecting a “wisdom of crowds” approach. With VRNA’s stock surpassing the average target price, this might be a pivotal moment for investors to reassess their investments. They are faced with a crucial decision: is the $47.28 target merely an interim stop on the way to even higher projections, or is the valuation becoming stretched, suggesting it might be prudent to take some profits? The table below summarizes the current ratings from analysts covering Verona Pharma plc (Adderbury):
| Recent VRNA Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong buy ratings: | 7 | 7 | 7 | 7 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 0 | 0 | 0 | 0 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.0 | 1.0 | 1.0 | 1.0 |
The average rating of 1.0 in the last row indicates a consensus of strong buy among analysts, with 1 representing a strong buy and 5 a strong sell. This article utilized data from Zacks Investment Research via Quandl.com. For the latest Zacks research report on VRNA, visit their website.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Funds Holding PKY
• ETFs Holding BR
• Institutional Holders of TSRI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
